文献速递神经CTMR

弥漫性胶质瘤非特指型:基于影像的风险分层实现组织分子水平的预后判断

Diffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication.
PubMed 文献 · Eur Radiol · 2022-05-19

回顾性纳入2011年1月至2020年12月间220例弥漫性胶质瘤非特指型患者,由两名神经放射科医生根据术前CT和MRI将肿瘤分为三种影像风险类型,并评估无进展生存期和总生存期。三种影像风险类型对无进展生存期和总生存期均有预后区分能力(log-rank检验,p < 0.001),影像生存模型1年无进展生存期和总生存期的AUC分别为0.772和0.650,与历史分子生存模型相似,且3年无进展生存期和5年总生存期的AUC分别为0.806和0.812,长期性能高。

要点

  • 基于影像的三种风险类型(低危、中危、高危)可在弥漫性胶质瘤非特指型中实现预后分层。
  • 影像生存模型1年无进展生存期AUC为0.772、总生存期AUC为0.650,与历史分子模型(无进展生存期AUC=0.74、总生存期AUC=0.87)相似。
  • 影像生存模型3年无进展生存期AUC为0.806、5年总生存期AUC为0.812,长期预后性能高。

核心结论

  • 基于影像的风险分层在弥漫性胶质瘤非特指型中实现了组织分子水平的预后判断,可能有助于指导分子诊断不足或失败患者的转诊。

研究设计与样本

  • 回顾性纳入2011年1月至2020年12月间220例弥漫性胶质瘤非特指型患者,由两名神经放射科医生分析术前CT和MRI,依据已知影像表型(如T2/FLAIR不匹配)将肿瘤分为三种影像风险类型。

关键影像表现/征象

  • 依据已知影像表型(如T2/FLAIR不匹配)将弥漫性胶质瘤非特指型分为低危、中危、高危三种影像风险类型。
  • 低危型预期为少突胶质细胞瘤、异柠檬酸脱氢酶(IDH)突变型且1p/19q共缺失。
  • 中危型预期为星形细胞瘤、IDH突变型。
  • 高危型预期为胶质母细胞瘤、IDH野生型。

诊断标准与关键数值

  • 三种影像风险类型对无进展生存期和总生存期均实现预后区分(log-rank检验,p < 0.001)。
  • 影像生存模型1年无进展生存期AUC为0.772,1年总生存期AUC为0.650。
  • 历史分子生存模型(基于2015年发表、采用癌症基因组图谱数据创建)无进展生存期AUC=0.74,总生存期AUC=0.87。
  • 影像生存模型3年无进展生存期AUC为0.806,5年总生存期AUC为0.812。
  • 时间依赖受试者工作特征分析采用10折交叉验证与100折自助法。

临床应用与阅片要点

  • 作者认为基于影像的风险分层可能有助于指导分子诊断不足或失败患者的转诊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether imaging-based risk stratification enables prognostication in diffuse glioma, NOS (not otherwise specified).

METHODS: Data from 220 patients classified as diffuse glioma, NOS, between January 2011 and December 2020 were retrospectively included. Two neuroradiologists analyzed pre-surgical CT and MRI to assign gliomas to the three imaging-based risk types considering well-known imaging phenotypes (e.g., T2/FLAIR mismatch). According to the 2021 World Health Organization classification, the three risk types included (1) low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant, and 1p/19q-codeleted; (2) intermediate-risk, expecting astrocytoma, IDH-mutant; and (3) high-risk, expecting glioblastoma, IDH-wildtype. Progression-free survival (PFS) and overall survival (OS) were estimated for each risk type. Time-dependent receiver operating characteristic analysis using 10-fold cross-validation with 100-fold bootstrapping was used to compare the performance of an imaging-based survival model with that of a historical molecular-based survival model published in 2015, created using The Cancer Genome Archive data.

RESULTS: Prognostication according to the three imaging-based risk types was achieved for both PFS and OS (log-rank test, p < 0.001). The imaging-based survival model showed high prognostic value, with areas under the curves (AUCs) of 0.772 and 0.650 for 1-year PFS and OS, respectively, similar to the historical molecular-based survival model (AUC = 0.74 for PFS and 0.87 for OS). The imaging-based survival model achieved high long-term performance in both 3-year PFS (AUC = 0.806) and 5-year OS (AUC = 0.812).

CONCLUSION: Imaging-based risk stratification achieved histomolecular-level prognostication in diffuse glioma, NOS, and could aid in guiding patient referral for insufficient or unsuccessful molecular diagnosis.

KEY POINTS: • Three imaging-based risk types enable distinct prognostication in diffuse glioma, NOS (not otherwise specified). • The imaging-based survival model achieved similar prognostic performance as a historical molecular-based survival model. • For long-term prognostication of 3 and 5 years, the imaging-based survival model showed high performance.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jang, Kim, Park, et al. Diffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication. Eur Radiol. 2022. PMID: 35587830. doi:10.1007/s00330-022-08850-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。